Serratia marcescens Peritonitis in a Diabetic Patient Receiving Continuous Ambulatory Peritoneal Dialysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We report a case of Serratia marcescens peritonitis in a 45-year-old man with insulin-dependent diabetes mellitus undergoing continuous ambulatory peritoneal dialysis (CAPD). The patient presented with abdominal pain and cloudy dialysate. Empiric antibiotic therapy was initiated intraperitoneally with cefazolin and ceftazidime for 5 days. Cultures of the dialysate revealed S. marcescens, and the treatment was subsequently changed to gentamicin and ceftazidime. Oral ciprofloxacin was also added. The patient’s abdominal pain and the dialysate white blood cell (WBC) count, however, did not improve. The indwelling CAPD catheter was therefore removed. This is an unusual case report in the Korean literature of S. marcescens peritonitis in a patient receiving CAPD.
Abstract
We report a case of Serratia marcescens peritonitis in a 45-year-old man with insulin-dependent diabetes mellitus undergoing continuous ambulatory peritoneal dialysis (CAPD). The patient presented with abdominal pain and cloudy dialysate. Empiric antibiotic therapy was initiated intraperitoneally with cefazolin and ceftazidime for 5 days. Cultures of the dialysate revealed S. marcescens, and the treatment was subsequently changed to gentamicin and ceftazidime. Oral ciprofloxacin was also added. The patient’s abdominal pain and the dialysate white blood cell (WBC) count, however, did not improve. The indwelling CAPD catheter was therefore removed. This is an unusual case report in the Korean literature of S. marcescens peritonitis in a patient receiving CAPD.
참고문헌 (14)
- Hejazi A, "Serratia marcescens", J Med Microbiol, 46, pp.903~912 (1997)
- Saklayen MG, "CAPD peritonitis. Incidence, pathogens, diagnosis,and management", Med Clin North Am, 74, pp.997~1010 (1990)
- Leblanc M, "Oral ciprofloxacin to treat bacterial peritonitisassociated with peritoneal dialysis", Clin Nephrol, 47, pp.350~ (1997)
- Vas S, "Changing picture of peritonitis in peritoneal dialysis", Am J Kidney Dis, 36, pp.1057~1058 (2000)
- Jarvis EM, "Predictors,treatment, and outcomes of non-Pseudomonas Gramnegativeperitonitis", Kidney Int, 78, pp.408~414 (2010)
- Szeto CC, "Change in bacterial etiology of peritonealdialysis-related peritonitis over 10 years: experience from acentre in South-East Asia", Clin Microbial Infect, 11, pp.837~839 (2005)
- Krishnan M, "Predictors of outcomefollowing bacterial peritonitis in peritoneal dialysis", PeritDial Int, 22, pp.573~581 (2002)
- Wilhelmi I, "Epidemic outbreak of Serratia marcescensinfection in a cardiac surgery unit", J Clin Microbiol, 25, pp.1298~1300 (1987)
- Haddy RI, "Nosocomial infectionin the community hospital: severe infection due to Serratiaspecies", J Fam Pract, 42, pp.273~277 (1996)
- Nikolaidis P, "Newer quinolones in the treatment of continuousambulatory peritoneal dialysis (CAPD) related infections", Perit Dial Int, 10, pp.127~133 (1990)
- Lee SH, "Clinical characteristics of relapsing peritonitisin CAPD patients", Korean J Nephrol, 16, pp.738~746 (1997)
- Bouza E, "Serratia bacteremia", Diagn MicrobiolInfect Dis, 7, pp.237~247 (1987)
- Chow KM, "Arisk analysis of continuous ambulatory peritoneal dialysisrelatedperitonitis", Perit Dial Int, 25, pp.374~379 (2005)
- Connacher AA, "Recurrent peritonitis caused by Serratia marcescensin a diabetic patient receiving continuous ambulatoryperitoneal dialysis", J Hosp Infect, 11, pp.155~160 (1988)